Search Results - "Rezk, Mourad F."

A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48) by Leng, Xiaomei, Leszczyński, Piotr, Jeka, Slawomir, Liu, Shengyun, Liu, Huaxiang, Miakisz, Malgorzata, Gu, Jieruo, Kilasonia, Lali, Stanislavchuk, Mykola, Yang, Xiaolei, Zhou, Yinbo, Dong, Qingfeng, Mitroiu, Marian, Addison, Janet, Rezk, Mourad F, Zeng, Xiaofeng

“…Equivalent efficacy and comparable pharmacokinetic, immunogenicity, and safety profiles of the biosimilar BAT1806/BIIB800 and reference tocilizumab (TCZ) in…”
Get full text

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review by Ebbers, Hans C., Pieper, Burkhard, Issa, Amine, Addison, Janet, Freudensprung, Ulrich, Rezk, Mourad F.

“…Introduction In 2016, SB4 (Benepali ® ) became the first etanercept (ETN) biosimilar to obtain marketing authorisation in Europe. Despite robust analytical and…”
Get full text

Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect by Rezk, Mourad F., Pieper, Burkhard

“…Over the years, biologic agents have proven their importance in the management of chronic autoimmune diseases, such as rheumatoid arthritis, psoriasis, and…”
Get full text

Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review by Rezk, Mourad F., Pieper, Burkhard

“…Immune-mediated inflammatory diseases (IMIDs) are chronic conditions that create a significant disease burden on millions of patients while adding a major…”
Get full text

To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars by Rezk, Mourad F., Pieper, Burkhard

“…In addition to the general clinical benefit offered, biosimilars may not only generate savings for healthcare budgets but also improve patient access to…”
Get full text

Correction to: Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review by Rezk, Mourad F., Pieper, Burkhard

“…In the original article, under the “Access to treatment” heading…”
Get full text

Correction to: To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars by Rezk, Mourad F., Pieper, Burkhard

“…The article “To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars”, written by Mourad F. Rezk and Burkhard Pieper was…”
Get full text

An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review by Hariprasad, Seenu M., Gale, Richard P., Weng, Christina Y., Ebbers, Hans C., Rezk, Mourad F., Tadayoni, Ramin

“…Biological therapies have revolutionized the treatment of disease across a number of therapeutic areas including retinal diseases. However, on occasion, such…”
Get full text